TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26420017
Drug: Neuromuscular blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blockers
Study: 26420017
Drug: O-SH-GA (opioids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-SH-GA (opioids, sedatives-hypnotics, general anaesthetics)
Study: 26420235
Drug: Navitoclax 150
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax 150 mg orally once daily plus erlotinib 150 mg orally once daily
Study: 26420235
Drug: Navitoclax 150
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax 150 mg/day
Study: 26420235
Drug: Navitoclax and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax and erlotinib combination
Study: 26420684
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (MTX, sulfasalazine, hydroxychloroquine)
Study: 26420854
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of TA-HPV
Study: 26421426
Drug: Combined sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m²/day administered D1-14 every 21 days)
Study: 26423260
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin (with potential escalation to 10 mg)
Study: 26423374
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg plus Elbasvir 50 mg once daily for 12 weeks
Study: 26423389
Drug: Whole-body insulin
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body insulin sensitivity (M value) assessed with hyperinsulinemic-euglycemic clamps
Study: 26423734
Drug: Supplements (β-carotene,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplements (β-carotene, vitamin C, α-tocopherol)
Study: 26423811
Drug: Panobinostat (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (20 mg) three times per week every other week for 8 weeks
Study: 26423811
Drug: Panobinostat (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (20 mg)
Study: 26423989
Drug: Maraviroc (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (600 mg twice daily)
Study: 26427534
Drug: Increased insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased insulin resistance in men
Study: 26427534
Drug: Increased insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased insulin resistance in women
Study: 26428249
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER (100-250 mg BID)
Study: 26428319
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) 1000 or 1500 mg/day (20 mg/kg/day, twice daily) and verapamil sustained-release tablets (120-240 mg/day)
Study: 26428319
Drug: Xenograft studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xenograft studies with similar dosing of HU and verapamil
Study: 26428486
Drug: Fludarabine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (30 mg/m(2)/day for 5 days on days -6 to -2) and melphalan (100 mg/m(2) on day -2)
Study: 26428486
Drug: Fludarabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine and melphalan conditioning therapy
Study: 26428846
Drug: Daily caloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily caloric intake during ICU stay
Study: 26429339
Drug: Clinician-supported inpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-supported inpatient self-managed insulin
Study: 26429745
Drug: Diagnosis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis and treatment strategy for obstructive sleep apnea (OSA)
Study: 26430465
Drug: Vitamin-D group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-D group (48 μg of vitamin-D + 800 mg calcium)
Study: 26430465
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (800 mg calcium)
Study: 26430892
Drug: ACR <30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACR <30 mg/g (reference group)
Study: 26432046
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg daily for the first 14 days of cycle 1 then continuously for subsequent cycles, combined with hyper-CVAD chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone, high-dose methotrexate, and cytarabine) every 21 days.
Study: 26432046
Drug: Ponatinib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib maintenance 45 mg daily with vincristine and prednisone monthly for 2 years followed by ponatinib indefinitely.
Study: 26432420
Drug: Antipsychotic treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antipsychotic treated SCZs
Study: 26432420
Drug: Antipsychotic free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic free SCZs
Study: 26433580
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.1 mg/m(2) (moderate impairment)
Study: 26433580
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 0.7 mg/m(2) (severe impairment)
Study: 26433580
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4 mg/m(2) (normal renal function)
Study: 26433580
Drug: Simulated dose
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated dose reduction to eribulin 1.1 mg/m(2) (moderate/severe renal impairment)
Study: 26435889
Drug: Cranial electrical
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial electrical stimulation (CES) applied via electrodes on the ear for 1 hour daily
Study: 26436130
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg per day (initially), later reduced to 30 mg or 15 mg per day due to tolerability issues, with aspirin 81 mg daily.
Study: 26436130
Drug: Ponatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib treatment (overall), with dose adjustments and monitoring.
Study: 26438349
Drug: Family planning
Normalized name: Lubricant Topical application Gel/Jelly [FAMILY PLANNING LIQUID LUBRICANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family planning and sexually transmitted infection treatment
Study: 26438497
Drug: Ciprofloxacin plus
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin plus amoxicillin-clavulanate
Study: 26438497
Drug: Empirical antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antibiotic combination therapy
Study: 26438614
Drug: Sulfonylurea (SU)
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea (SU) therapy
Study: 26439129
Drug: MVA Smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA Smallpox Vaccine (IMVAMUNE), 2 doses subcutaneously, 4 weeks apart
Study: 26439129
Drug: MVA Smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA Smallpox Vaccine (IMVAMUNE)
Study: 26439886
Drug: Intracavernous autologous
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous autologous bone marrow-mononuclear cells (BM-MNCs) injection
Study: 26439886
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of BM-MNCs
Study: 26439886
Drug: Intracavernous autologous
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous autologous BM-MNC injection
Study: 26440706
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose arsenic trioxide (0.005 mg/kg/day for 3 days) administered before chemotherapy cycles 2, 4, and 6
Study: 26440706
Drug: Chemotherapy cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy cycles 1, 3, and 5 (baseline)
Study: 26442234
Drug: Myofascial structural
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial structural integration therapy (n=15)
Study: 26444282
Drug: Anakinra (ANA)
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra (ANA) 100 mg daily for one year
Study: 26445139
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin (400 mg; positive control)
Study: 26446491
Drug: DJBL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DJBL treatment
Study: 26447761
Drug: od-value thresholds
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: od-value thresholds for infarct size > 100 ml
Study: 26447761
Drug: od-value thresholds
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: od-value thresholds for infarct size > 70 ml
Study: 26448169
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of substance P-derived peptide FGLM-amide and IGF-1-derived peptide SSSR
Study: 26448169
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P and insulin-like growth factor 1 (IGF-1)
Study: 26448724
Drug: Variable dose
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dose warfarin (first dose on the night preceding surgery with subsequent target INR 2.0-2.5)
Study: 26448724
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg daily starting 6-18 h postoperatively
Study: 26448724
Drug: Fixed 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed 1.0 mg dose warfarin daily starting 7 days preoperatively
Study: 26448724
Drug: Fixed low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed low dose warfarin
Study: 26448901
Drug: Oral QLT091001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral QLT091001 administered once daily for 7 days
Study: 26449224
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of temozolomide (TMZ) 150 mg/m² PO daily on days 1-5 and veliparib (ABT-888) 40 mg PO daily on days 1-7 of a 28-day cycle
Study: 26449224
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of temozolomide (TMZ) and veliparib (ABT-888)
Study: 26450421
Drug: Standard-dose BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose BCG SSI
Study: 26450421
Drug: Standard-dose BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose BCG TICE
Study: 26450421
Drug: High-dose BCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BCG SSI
Study: 26450421
Drug: High-dose BCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BCG TICE
Study: 26451310
Drug: Autologous or
Normalized name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous or donor-derived T cells expressing CD19 chimeric antigen receptors (CARs) with 4-1BB and CD3ζ moiety
Study: 26451310
Drug: Conditioning chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning chemotherapy
Study: 26451310
Drug: No conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: No conditioning chemotherapy
Study: 26452027
Drug: cfDNA analysis
Normalized name: CFDN
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cfDNA analysis during cetuximab-based treatment
Study: 26452027
Drug: cfDNA analysis
Normalized name: CFDN
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cfDNA analysis during cetuximab/irinotecan chemotherapy
Study: 26452397
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of herpes zoster vaccine (ZV) administered to participants aged ≥ 70 years.
Study: 26452397
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of herpes zoster vaccine (ZV) administered to age-matched groups (100 participants aged 50-59 years, 100 aged 60-69 years, and 200 aged ≥ 70 years).
Study: 26452405
Drug: 14-day tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day tailored therapy based on H. pylori culture and MIC test
Study: 26452405
Drug: 14-day EBMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day EBMT therapy
Study: 26452405
Drug: 14-day MEA
Normalized name: MEA
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day MEA therapy
Study: 26452561
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of one neuromuscular blocking agent (NMBA)
Study: 26452561
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from neostigmine administration to endotracheal extubation ≥10 min
Study: 26452561
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from last NMBA administration to endotracheal extubation ≥60 min
Study: 26453446
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz deep rTMS (1200 pulses) over the mPFC, followed by nine additional sessions of daily rTMS
Study: 26453479
Drug: Philips fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Philips fluid accumulation vest (FAV) used for daily monitoring of transthoracic bioimpedance for 45 days post-discharge.
Study: 26453983
Drug: Progesterone on
Normalized name: Progesterone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone on hCG day (mean ± SD: 1.13 ± 0.69 ng/mL) among agonist-treated patients
Study: 26453983
Drug: Progesterone on
Normalized name: Progesterone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone on hCG day (mean ± SD: 1.11 ± 0.58 ng/mL) among recombinant FSH stimulation
Study: 26454362
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin I assay, concentrations less than 5 ng/L
Study: 26454362
Drug: Troponin concentration
Normalized name: atropine sulfate Ophthalmic Solution [Ocu-tropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin concentration of 5 ng/L or more
Study: 26454612
Drug: Dose-Dense Paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-Dense Paclitaxel, Trastuzumab, and Lapatinib (PTL)
Study: 26457065
Drug: Natural micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural micronized progesterone vaginal tablet (FE 999913) administered twice daily
Study: 26457225
Drug: Generic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic drugs perception assessment
Study: 26457568
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (5 g daily for 8 weeks)
Study: 26458184
Drug: DSM symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM symptoms (e.g., sad mood)
Study: 26458184
Drug: Non-DSM symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-DSM symptoms (e.g., anxiety)
Study: 26458804
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg DEN1-80E with 1.25 mg of elemental aluminum
Study: 26458804
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg DEN1-80E with 1.25 mg of elemental aluminum
Study: 26459220
Drug: (11)C Pittsburgh
Normalized name: Choline C 11
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (11)C Pittsburgh compound B (PIB) PET scan to quantify global amyloid deposition
Study: 26459405
Drug: Global cardiovascular
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Global cardiovascular assessment through clinical exam, instrumental tests (electrocardiogram, echocardiogram), and biological parameters
Study: 26459405
Drug: Biological collection
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological collection on plasma and urine
Study: 26459812
Drug: Sunitinib or
Normalized name: sunitinib Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib or Cediranib (VEGF receptor inhibition)
Study: 26459996
Drug: Haigis-L formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haigis-L formula
Study: 26460303
Drug: Vemurafenib (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (960 mg orally twice a day)
Study: 26465780
Drug: Darapladib 160
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib 160 mg orally, once daily for 28 days
Study: 26465780
Drug: Darapladib 160
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib 160 mg on Day 28
Study: 26468043
Drug: Serologically confirmed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serologically confirmed pertussis infection (anti-PT IgG titre ⩾62·5 IU/ml)
Study: 26471772
Drug: Incidence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidence of residual hip pain and analgesics use
Study: 26472037
Drug: Appropriate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate antibiotic treatment for tracheobronchitis
Study: 26472037
Drug: Inappropriate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate antibiotic treatment for tracheobronchitis
Study: 26472751
Drug: Idelalisib 150
Normalized name: idelalisib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib 150 mg twice daily continuously for 48 weeks plus rituximab 375 mg/m(2) weekly ×8
Study: 26473643
Drug: AZD9291 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 at doses of 20 to 80 mg/day
Study: 26474292
Drug: Weighted endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weighted endurance exercise (LC) with EAA supplementation (10 g EAA, 3.6 g leucine)
Study: 26474292
Drug: Conventional endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional endurance exercise (CE) with EAA supplementation (10 g EAA, 3.6 g leucine)
Study: 26474521
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy followed by local excision (capecitabine 725 mg/m² twice daily, oxaliplatin 50 mg/m², radiation 50.4 Gy total)
Study: 26476290
Drug: ombitasvir/paritaprevir/ritonavir (25/150/100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ombitasvir/paritaprevir/ritonavir (25/150/100mg once daily) and dasabuvir (250mg twice daily) for 12 weeks
Study: 26479222
Drug: Antipsychotic dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic dosing regimen, specific details not available
Study: 26479487
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) for treatment-resistant MDD and BPII depression
Study: 26479487
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) for treatment-resistant MDD
Study: 26479487
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) for treatment-resistant BPII depression
Study: 26481067
Drug: Prophylactic intra-abdominal
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intra-abdominal drainage following rectal resection
Study: 26482301
Drug: Rifabutin treatment
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin treatment
Study: 26482312
Drug: Telavancin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin (10 mg/kg/day for CLCR >50 ml/min; 7.5 mg/kg/day for CLCR 30-49 ml/min)
Study: 26482376
Drug: Sodium tanshinone
Normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days) in addition to standard therapy
Study: 26482895
Drug: Renal sympathetic
Normalized name: Bos taurus sympathetic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal sympathetic denervation (RSD) via endovascular radiofrequency ablation (RFA) of the renal arteries, with continued full-dose antihypertensive therapy (4.1 drugs) including diuretics.
Study: 26483108
Drug: Statin-based LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-based LDL-C lowering therapy
Study: 26483516
Drug: Telaprevir-based therapy
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir-based therapy (750 mg every 8 hours, 1125 mg if on efavirenz) plus Peg-IFNα2a (180 μg/week) and ribavirin (800 mg/day) for 12 weeks, followed by Peg-IFNα2a and ribavirin alone for 12 or 36 weeks depending on patient type.
Study: 26483516
Drug: Telaprevir-based therapy
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir-based therapy
Study: 26486517
Drug: Tariquidar (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tariquidar (2 mg/kg)
Study: 26486517
Drug: Tariquidar in
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tariquidar in combination with docetaxel